Pfizer Inc. (NYSE:PFE) drug pipeline took a hit with the announcement Monday that an experimental treatment for non-small cell lung cancer failed in key studies to show a significant effect on patient survival. Pfizer Inc. (NYSE:PFE) stock opened at $30.24 in last session, and closed at $30.11, while the day range of stock is $30.00 – $30.46. The stock showed a negative weekly performance of -3.71%.
Just one week after disclosing its shaky fourth-quarter financial figures, Abbott Laboratories (NYSE:ABT) laid off an unspecified number of employees at its North Chicago, Ill., headquarters on Tuesday. Abbott Laboratories (NYSE:ABT) stock opened at $36.26, in last session and closed at $35.85, by losing -1.43%. The 52 week range of the stock is $32.70 – $39.86. Company’s market capitalization is $55.43 billion.
Merck & Co., Inc. (NYSE:MRK) has turned an important corner in getting its allergy treatment Ragwitek to the market after FDA advisory panel backed the drug based on the available data. The panel voted 6-2 in favor of the drug’s efficacy and safety, with one panel member abstaining from the decision. Merck & Co., Inc. (NYSE:MRK) is fronting Ragwitek as oral allergy treatment to counter the standard injection medications. Merck & Co., Inc. (NYSE:MRK) stock decreased -1.25% and finished the last session at $52.21. The EPS of the stock remained 1.51. Company’s market capitalization is $152.80 billion.
Gilead Sciences, Inc (NASDAQ:GILD) was downgraded by Zacks from an “outperform” rating to a “neutral” rating in a research report issued to clients and investors on Wednesday, Analyst Ratings News reports. They currently have a $85.00 price target on the stock. Gilead Sciences, Inc. (NASDAQ:GILD) stock opened the session at $80.01, and closed the session at $79.85. The 52 week range of the stock remained $39.24 – $84.40 and the day range was $78.96 – $81.09.